XTX Topco Ltd Grows Stake in The Oncology Institute, Inc. (NASDAQ:TOI)

XTX Topco Ltd increased its position in The Oncology Institute, Inc. (NASDAQ:TOI) by 49.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 55,698 shares of the company’s stock after purchasing an additional 18,448 shares during the quarter. XTX Topco Ltd owned approximately 0.07% of Oncology Institute worth $63,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Jane Street Group LLC lifted its stake in shares of Oncology Institute by 613.6% in the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock valued at $39,000 after purchasing an additional 109,769 shares during the period. 36.86% of the stock is currently owned by institutional investors.

Oncology Institute Stock Up 2.5%

TOI stock opened at $3.76 on Friday. The Oncology Institute, Inc. has a twelve month low of $0.13 and a twelve month high of $4.50. The company has a quick ratio of 1.59, a current ratio of 1.62 and a debt-to-equity ratio of 14.58. The firm has a market cap of $335.50 million, a PE ratio of -5.53 and a beta of 0.08. The business has a 50 day moving average of $3.10 and a 200 day moving average of $2.21.

Oncology Institute (NASDAQ:TOI) last posted its earnings results on Wednesday, May 14th. The company reported ($0.18) EPS for the quarter. The business had revenue of $104.41 million during the quarter. Oncology Institute had a negative return on equity of 1,527.21% and a negative net margin of 14.26%.

Insiders Place Their Bets

In other Oncology Institute news, Director Brad Hively sold 1,976,137 shares of Oncology Institute stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $2.87, for a total value of $5,671,513.19. Following the completion of the sale, the director owned 603,501 shares of the company’s stock, valued at approximately $1,732,047.87. This trade represents a 76.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Growth I. L.P. M33 sold 76,324 shares of Oncology Institute stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $3.05, for a total value of $232,788.20. Following the completion of the sale, the director directly owned 1,272,724 shares of the company’s stock, valued at approximately $3,881,808.20. The trade was a 5.66% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 4,726,137 shares of company stock valued at $13,379,013. Corporate insiders own 8.50% of the company’s stock.

Analyst Ratings Changes

TOI has been the subject of a number of analyst reports. B. Riley initiated coverage on Oncology Institute in a research report on Wednesday, July 16th. They set a “buy” rating and a $6.00 price objective for the company. BTIG Research initiated coverage on Oncology Institute in a research report on Thursday, May 15th. They set a “buy” rating and a $7.00 price objective for the company. Finally, Noble Financial initiated coverage on Oncology Institute in a research report on Wednesday, July 23rd. They set an “outperform” rating and a $8.00 price objective for the company.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.